Half-Year 2022 Financial and Clinical Trials Update

CER sales growth (%) Quarterly development 2021 vs. 2020 2022 vs. 2021 Q1 Q2 Q3 Q4 Q1 Q2 Pharmaceuticals Division -9 4 5 LO 14 19 6 0 United States -14 0 0 8 2 1 Europe -6 15 1 19 -1 -6 Japan -7 7 60 46 69 International 0 4 2 9 0 Diagnostics Division 55 48 18 8 24 Roche Group 3 14 8 12 11 MOO 3 4 0 0 CER-Constant Exchange Rates Roche 169

View entire presentation